Gabather

0,07

SEK

0 %

Mindre end 1K følgere

GABA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Finansielt overblik og estimater

Ownership

0%

+69,59%

-34,49%

-45,41%

-56,33%

-69,15%

-93,19%

-94,16%

-98,35%

Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.

Markedsværdi

51,44 mio. SEK

Aktieomsætning

381,95 SEK

Omsætning

-

EBIT %

-

P/E

-

Udbytteafkast, %

-

Finanskalender

28.5

2025

Delårsrapport Q1'25

30.6

2025

Generalforsamling '25

28.8

2025

Delårsrapport Q2'25

ViserAlle indholdstyper

Selskabsmeddelelse13.1.2025, 07.30

Gabather AB appoints Pareto Securities AB to act as a liquidity provider for the Company's share

Selskabsmeddelelse10.4.2024, 11.00

Gabather AB: Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

Pressemeddelelse18.3.2024, 07.30

Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Pressemeddelelse7.3.2024, 08.02

Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study

Selskabsmeddelelse22.12.2023, 14.03

Gabather AB receives initial EEG data analysis from the GT-002 target engagement study

Selskabsmeddelelse14.12.2023, 08.16

Gabather AB initiates discussions with specialist doctors and researchers at Karolinska Institutet for the design of a study in individuals at risk of developing frontotemporal dementia (FTD)

Selskabsmeddelelse11.12.2023, 12.23

Gabather AB broadens the scope of EEG data analysis generated during the target engagement study by partnering with MINDIG

Selskabsmeddelelse12.10.2023, 12.00

Gabather AB: Gabather Announces Completion of Phase I EEG/fMRI Target Engagement Study of GT-002 in Healthy Volunteers

Selskabsmeddelelse13.4.2023, 06.45

Gabather AB: Gabather, Receives Notice of Approval from the Japanese Patent Office (JPO) for its National Phase Application No. 2020-554957

Selskabsmeddelelse7.6.2022, 08.57

Gabather AB, receives Notice of Allowance from the U.S. Patent Office for its U.S. patent application publication No. US 2021/0087193 A1

Pressemeddelelse2.6.2022, 08.00

Gabather AB: BioStock: Gabather's lead candidate moves forward in the clinic

Selskabsmeddelelse17.5.2022, 13.36

Gabather AB: Gabather receives approval to start the EEG/fMRI target engagement study with the drug candidate GT-002

Selskabsmeddelelse22.3.2022, 08.00

Gabather AB invited by the Alzheimer's Drug Discovery Foundation, USA to submit a grant application to expand the studies with GT-002 in preclinical models of Alzheimer's disease

Selskabsmeddelelse14.9.2021, 06.37

Gabather AB: BioStock: Gabather poised to complete phase I with GT-002

Selskabsmeddelelse10.5.2021, 08.19

Gabather AB: BioStock: Covid unmasks need for better mental health medication

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.